Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns (CORTISoL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02700828
Recruitment Status : Active, not recruiting
First Posted : March 7, 2016
Last Update Posted : April 18, 2018
Sponsor:
Information provided by (Responsible Party):
Ágnes Jermendy, Semmelweis University

Brief Summary:

This is a prospective, randomized, double-blind, placebo controlled, single center study to compare low dose hydrocortisone vs placebo in systemic low blood pressure during hypothermia treatment in asphyxiated newborns. Patients will be allocated to one of the treatment arms (hydrocortisone or placebo) while receiving conventional inotropic therapy as needed.

The hypothesis is that cooled asphyxiated neonates develop relative adrenal insufficiency that may contribute to hypotension and lower efficacy of inotropic therapy in this patient population. Thus, the investigators are planning to measure initial serum cortisol levels and investigate the cardiovascular effects of low dose hydrocortisone supplementation besides conventional inotropic therapy in a placebo-controlled fashion.


Condition or disease Intervention/treatment Phase
Hypoxic-Ischemic Encephalopathy Asphyxia Drug: Hydrocortisone Drug: Placebo Phase 2 Phase 3

Detailed Description:

Hypothesis:

The researchers hypothesized that asphyxiated neonates undergoing therapeutic hypothermia develop relative adrenal insufficiency that contributes to "late onset" (>24 hours after birth) hypotension resistant to optimized pharmacological support.

Thus, the investigators are planning to measure initial serum cortisol levels and investigate the cardiovascular effects of low dose hydrocortisone supplementation.

Specific aims:

  1. To study initial serum cortisol levels in asphyxiated newborns undergoing therapeutic hypothermia with late onset hypotension.
  2. To demonstrate that in asphyxiated newborns undergoing therapeutic hypothermia and presenting with systemic hypotension resistant to optimized pharmacological support, low dose hydrocortisone supplementation restores normal blood pressure when compared to placebo.

Methodology:

  • Prospective, randomized, double-blind, single center, cohort study
  • 1st Department of Paediatrics, NICU, Semmelweis University, Hungary
  • Starting date: 02/14/2016
  • Patient number: 16 vs 16 (hydrocortisone vs placebo - based on previous observational study results)
  • Intervention (hydrocortisone vs placebo) applied only during therapeutic hypothermia (max. 72 hours)
  • Neurodevelopmental follow-up visit: Bayley II/III scale to evaluate the effect of hydrocortisone treatment on the neurological development at the age between 18 and 22 months.

Drugs for hypotension, the hydrocortisone protocol:

  1. Fluid replacement (volume bolus: 10-20 ml/kg isotonic saline, over 15 minutes, according to the clinician's decision)
  2. In case of persisting hypotension: serum sample is collected for cortisol measurement.
  3. Randomization, irrespective of actual cortisol level. As the study is blinded, enrollment in the clinical trial will/shall not influence the clinical decision making about further interventions. A dedicated study assistant will be available to prepare the drug / placebo for the newborns.

    • Inotropic therapy (dopamine, following the standard titration protocol)
    • AND (at start of dopamine) hydrocortisone: 4 * 0,5 mg/kg /24 hours (in every 6 hours) or placebo administration (the corresponding amount of isotonic saline)
  4. After randomization, intervention is continued until the end of hypothermia treatment (max. 72 hours), with the same dose. Inotropic therapy will be titrated as needed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Prospective, Randomized, Double-blind, Cohort Study of Hydrocortisone vs Placebo in Systemic Low Blood Pressure During Hypothermia Treatment in Asphyxiated Newborns
Study Start Date : February 2016
Actual Primary Completion Date : November 2017
Estimated Study Completion Date : February 2020


Arm Intervention/treatment
Active Comparator: Hydrocortisone
Hydrocortisone is the pharmaceutical term for cortisol, the principal glucocorticoid secreted by the adrenal gland
Drug: Hydrocortisone
4 * 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
Other Name: Solu-Cortef

Placebo Comparator: Placebo
Isotonic sodium chloride is an aqueous solution of 0.9 percent sodium chloride which is isotonic with the blood and tissue fluid
Drug: Placebo
4 * 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
Other Name: Isotonic saline




Primary Outcome Measures :
  1. Compare mean arterial blood pressure (MAP) change in the patients receiving hydrocortisone vs placebo [ Time Frame: 2 hours ]
    Circulatory stability as measured by an increased MAP (5 mmHg) within two hours after drug administration


Secondary Outcome Measures :
  1. Frequency of initially low serum cortisol in hypotensive asphyxiated newborns undergoing therapeutic hypothermia [ Time Frame: before hydrocortisone administration within max. 72 hours ]
    Initially low serum cortisol - proven relative adrenal insufficiency

  2. Length of dopamine treatment in the patients receiving hydrocortisone vs placebo [ Time Frame: 72 hours ]
    Compare dopamine treatment's length (in hours) in the patients receiving hydrocortisone vs placebo

  3. Cumulative dopamine dose in the patients receiving hydrocortisone vs placebo [ Time Frame: 72 hours ]
    Compare cumulative dopamine dose (mcg/kg) in the patients receiving hydrocortisone vs placebo

  4. Change in hourly diuresis in the patients receiving hydrocortisone vs placebo [ Time Frame: 72 hours ]
    Measure and compare the hourly diuresis (ml/kg/hour) in the patients receiving hydrocortisone vs placebo

  5. Change in the echocardiography parameters (fractional shortening and cardiac output) in the patients receiving hydrocortisone vs placebo [ Time Frame: 72 hours ]
    Fractional shortening (FS%) and cardiac output (CO in ml/kg/min) measurements before and after hydrocortisone or placebo, during the first 72 hours (during hypothermia treatment)

  6. Long term neurodevelopmental outcome in the patients receiving hydrocortisone vs placebo [ Time Frame: 18-22 month ]
    Performance on motor and mental scales of Bayley II/III scales of infant development



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 72 Hours   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The infant will be assessed sequentially by criteria A, B and C, as described by the TOBY trial and listed below, to be eligible for hypothermia treatment.

    A. Infants ≥ 36 completed weeks of gestation admitted to the NICU with at least one of the following:

    • Apgar score of ≤ 5 at 10 minutes after birth
    • Continued need for resuscitation, including endotracheal or mask ventilation, at 10 minutes after birth
    • Acidosis within 60 minutes of birth (defined as any occurrence of umbilical cord, arterial or capillary pH < 7.00)
    • Base Deficit ≥ 16 mmol/L in umbilical cord or any blood sample (arterial, venous or capillary) within 60 minutes of birth

    B. Moderate to severe encephalopathy, consisting of altered state of consciousness (lethargy, stupor or coma) AND at least one of the following:

    • hypotonia
    • abnormal reflexes including oculomotor or pupillary abnormalities
    • absent or weak suck
    • clinical seizures

    C. At least 30 minutes duration of aEEG recording that shows abnormal background aEEG activity or seizures. There must be one of the following:

    • normal background with some seizure activity
    • moderately abnormal activity
    • suppressed activity
    • continuous seizure activity
  2. Invasive arterial blood pressure measurement: umbilical arterial catheter or peripheral arterial catheter to measure invasively the arterial blood pressure.
  3. During hypothermia treatment low blood pressure was detected and treated with the following:

    • fluid therapy: 10-20 ml/kg isotonic NaCl if hypotension is still present
    • inotropic therapy: dopamine in parallel with study intervention
  4. A written informed consent has been obtained from a parent of each infant after explanation of the study.

Exclusion Criteria:

  1. Signed informed consent is unavailable.
  2. Infants who are expected to be > 6 hours of age (not suitable for cooling).
  3. Congenital abnormalities, cardiac anomalies, meconium aspiration syndrome.
  4. Low blood pressure coincides with high heart rate (>120/min) in cooled infants, suggesting hypovolaemia.
  5. Haematocrit level < 35%.
  6. Need for combined, ≥2 types of inotropic therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02700828


Locations
Layout table for location information
Hungary
Semmelweis University, 1st Department of Paediatrics
Budapest, Pest, Hungary, 1083
Sponsors and Collaborators
Semmelweis University
Investigators
Layout table for investigator information
Study Director: Miklós Szabó, MD, PhD Semmelweis University, 1st Department of Paediatrics

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ágnes Jermendy, assistant lecturer, Semmelweis University
ClinicalTrials.gov Identifier: NCT02700828     History of Changes
Other Study ID Numbers: 1Ped-AsphCort 001
First Posted: March 7, 2016    Key Record Dates
Last Update Posted: April 18, 2018
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Ágnes Jermendy, Semmelweis University:
Hypothermia treatment
Circulatory failure
Neonatal hypotension
Relative adrenal insufficiency
Hydrocortisone supplementation
Additional relevant MeSH terms:
Layout table for MeSH terms
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Brain Diseases
Brain Ischemia
Hypoxia-Ischemia, Brain
Hypotension
Hypothermia
Asphyxia
Central Nervous System Diseases
Nervous System Diseases
Body Temperature Changes
Signs and Symptoms
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Hypoxia, Brain
Death
Pathologic Processes
Wounds and Injuries
Anti-Inflammatory Agents